UltraGreen.ai Expected to Miss 2026 Revenue Guidance

Dow Jones10-30

0753 GMT - UltraGreen.ai's 2026 revenue is likely to miss its guidance as competitive pressure emerged in 4Q, earlier than the diagnostic imaging dye maker previously expected, say DBS Group Research's Amanda Tan in a note. UltraGreen's volume losses to competitor Zydus Lifesciences are likely to exceed the bank's prior expectations, as Zydus started marketing its product in August, before UltraGreen relaunched its generic version, she says. This likely allowed Zydus to secure price-sensitive accounts before UltraGreen could respond, she says. The analyst trims her 2026-2027 earnings estimates by 4%-13% to reflect likely volume pressure and weaker pricing. DBS cuts its target price to 50 cents from 65 cents and maintains a hold rating. Shares fall 4.2% to US$0.455.

 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment